Imatinib
Mostrando 1-12 de 100 artigos, teses e dissertações.
-
1. Friedelane Triterpenes with Cytotoxic Activity from the Leaves of Maytenus quadrangulata (Celastraceae)
Three new triterpenes, 3,4-seco-3,11β-epoxyfriedel-4(23)-en-3β-ol (1), friedelan-3α,11β diol (2), 7β,26-epoxyfriedelan-3a,7a-diol (3), a mixture of two new triterpenes 3α-hydroxyfriedelan-29-yl palmitate (4) and 3α-hydroxyfriedelan-29-yl stearate (5) and eleven known compounds were obtained from the hexane extract of Maytenus quadrangulata leaves. The
Journal of the Brazilian Chemical Society. Publicado em: 2022
-
2. Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery. A case report
RESUMO Mimosa caesalpiniifolia Benth. (Fabaceae) é uma árvore nativa das florestas tropicais secas do Nordeste do Brasil e pode ser explorada para fins madeireiros e reflorestamento. Este estudo avaliou a qualidade fisiológica de sementes e a diversidade genética de uma população cultivada de M. caesalpiniifolia, tendo como base de sustentação o pote
Hematol., Transfus. Cell Ther.. Publicado em: 2020-10
-
3. Blepharospasm and periorbital edema after imatinib mesylate: improvement with botulinum toxin
Arq. Neuro-Psiquiatr.. Publicado em: 20/01/2020
-
4. Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase
ABSTRACT Introduction: The incidence of grade 3-4 anemia was reported to be 3% with imatinib therapy for newly diagnosed chronic myeloid leukemia (CML) in the chronic phase (CP). However, there are few data regarding the causes and the development of anemia after long-term treatment. This study aimed to evaluate the incidence of anemia after at least two ye
Hematol., Transfus. Cell Ther.. Publicado em: 25/11/2019
-
5. What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?
ABSTRACT Objective: To assess clinical outcomes of intolerant, relapsed or refractory patients who could not be treated with new tyrosine kinase inhibitors or experimental therapies. Methods: A retrospective cohort of 90 chronic myeloid leukemia patients in all phases of the disease treated with imatinib mesylate as their first TKI therapy, and with dasati
Hematol., Transfus. Cell Ther.. Publicado em: 10/10/2019
-
6. Scientific comment on: "Analysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the Brazilian Amazon". Who likes to take medicine forever?
Hematol., Transfus. Cell Ther.. Publicado em: 10/06/2019
-
7. Analysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the Brazilian Amazon
ABSTRACT Background: There has been a revolution in the treatment of Chronic Myeloid Leukemia since imatinib's introduction. However, patient adherence has a great impact on the response obtained with medical treatment. This study's objective was to analyze the drug adherence and the factors that influenced it in patients with Chronic Myeloid Leukemia in a
Hematol., Transfus. Cell Ther.. Publicado em: 10/06/2019
-
8. Downregulation of lncRNA CCDC26 contributes to imatinib resistance in human gastrointestinal stromal tumors through IGF-1R upregulation
Imatinib is the first line of therapy for patients with metastatic or gastrointestinal stromal tumors (GIST). However, drug resistance limits the long-term effect of imatinib. Long non-coding RNAs (lncRNAs) are emerging as key players in regulating drug resistance in cancer. In this study, we investigated the association between lncRNA CCDC26 and IGF-1R in G
Braz J Med Biol Res. Publicado em: 03/06/2019
-
9. PRE-OPERATIVE GASTRIC GIST DOWNSIZING: THE IMPORTANCE OF NEOADJUVANT THERAPY
RESUMO Introdução: O tumor estromal gastrintestinal (GIST) gástrico é neoplasia que cursa, por vezes, com apresentação assintomática, se manifestando como massa abdominal, relacionada a casos mais avançados. Esses, por sua vez, exigem tratamento com operações maiores e que cursam com mais alta morbimortalidade. Objetivo: Revisar e atualizar o tra
ABCD, arq. bras. cir. dig.. Publicado em: 07/02/2019
-
10. Cytotoxic and pro-apoptotic action of MjTX-I, a phospholipase A2 isolated from Bothrops moojeni snake venom, towards leukemic cells
Abstract Background: Chronic myeloid leukemia (CML) is a BCR-ABL1+ myeloproliferative neoplasm marked by increased myeloproliferation and presence of leukemic cells resistant to apoptosis. The current first-line therapy for CML is administration of the tyrosine kinase inhibitors imatinib mesylate, dasatinib or nilotinib. Although effective to treat CML, som
J. Venom. Anim. Toxins incl. Trop. Dis. Publicado em: 24/01/2019
-
11. Hepatic protective effect of grape seed proanthocyanidin extract against Gleevec-induced apoptosis, liver Injury and Ki67 alterations in rats
ABSTRACT Gleevec (imatinib) is an antineoplastic chemotherapeutic agent used in the treatment of many types of cancer. The current study was conducted to examine the possible modifying effects of grape seeds proanthocyandins extract (GSPE) against apoptosis, liver injury and Ki67 alterations induced by Gleevec in male rats. 40 male albino rats were equally d
Braz. J. Pharm. Sci.. Publicado em: 26/07/2018
-
12. Synthesis, characterization and biological activity of a gold(I) triazenide complex against chronic myeloid leukemia cells and biofilm producing microorganisms
ABSTRACT The enhancement of anti-leukemia therapy and the treatment of infections caused by multidrug-resistant pathogens are major challenges in healthcare. Although a large arsenal of drugs is available, many of these become ineffective, and as a result, the discovery of new active substances occurs. Notably, triazenes (TZCs) have been consolidated as a pr
Braz. J. Pharm. Sci.. Publicado em: 09/04/2018